People · Operator
Named in public records as an officer, director or promoter · active 2009–2022 · Biotechnology, Other Health Care, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Deepcell, Inc. | — | Biotechnology | Series C | $96.9M | $1.7B | 2019 |
| ProMed Inc | — | Other Health Care | Series A | $21.9M | $30.3M | 2009 |
| Simpirica Spine, Inc. | — | Other Technology | Series A | $20.0M | $138.7M | 2013 |
| Genten Therapeutics, Inc. | — | Biotechnology | Series A | $12.0M | $433.8M | 2016 |
| CRS Bio, Inc. | — | Biotechnology | Series A | $8.4M | $303.7M | 2016 |
| Thrive Agrobiotics, Inc. | — | Biotechnology | Series A | $6.7M | $241.0M | 2016 |
| Exotech Bio, Inc. | — | Biotechnology | Series A | $5.0M | $180.8M | 2016 |
| Relieve Genetics, Inc. | — | Biotechnology | Series A | $4.3M | $156.7M | 2016 |
| AD Skincare, Inc. | — | Other Health Care | Series A | $4.3M | $87.5M | 2016 |
| Fliqz Inc | — | Other Technology | Seed | $1.0M | $34.1M | 2009 |
David Mauney at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside David Mauney on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.